Six months ago, we published an in-depth review of the cell-based immunotherapy landscape, including forward-facing declarations of 2020 data releases, filings, etc. In this paper, we look at how the environment has evolved, provide updates on key developmental therapies, and look at how the rest of 2020 is likely to go.
